preview

Chronic Disease: The Ebola Virus

Decent Essays

Fever, severe headache, joint and muscle aches, the chills and weakness (Mayo Clinic Staff, 2014). Those are just some of the early symptoms of Zaire ebolavirus. This virus is also known as EBOV, Ebola hemorrhagic fever, and the Ebola virus (Mulherkar, Raaben, Torre, Whelan, & Chandran, 2011). A couple days after the early symptoms appear, infected people start to feel nausea, vomit, have bloody diarrhea, red eyes, raised rash, chest pain and cough, stomach pain, severe weight loss, bleeding from the eyes and internal bleeding. Within days of infection, and without proper treatment, the infected person perishes (Mayo Clinic Staff, 2014). However, with a vaccine that would prevent the spread of Ebola, people may never experience these symptoms …show more content…

Also, the Center for Disease Control and Prevention lists Ebola as a Category A Bioterrorism Agent, making it’s prevention and/or care of the upmost priority (Levine, Tapia, Hill, & Sow, 2014). The chance of perishing from the disease differs depending on several different factors. These include but are not limited to, density of population, healthcare infrastructure, and financial resources (Seppa, 2014). Liberia, Guinea and Sierra Leone, the countries in Western Africa most heavily hit by Ebola, have dense populations, poor healthcare infrastructure and a lack of financial resources (Seppa, 2014). Additionally, none have dealt with the Ebola virus before, resulting in only two-trained health care workers for every 55 patients (Seppa, 2014). That ratio would be more balanced if health care workers did not abandon their post, likely due to fear, because about 10% of the deaths in this current epidemic are health care workers that were infected while treating infected people. The World Health Organization declared the current West African Ebola epidemic an international health emergency (Seppa, …show more content…

Unlike most vaccines, it does not contain any Zaire ebolavirus nor any other strain of the disease (National Institute of Health, 2014). This eliminates the possibility of the vaccine causing a person injected with the vaccine to get sick because of it. cAd3-EBOV is one of the two Ebola vaccines that are further along in clinical trials. cAd3-EBOV has shown 100% effectiveness in nonhuman primates. cAd3-EBOV is being tested in both a monovalent form and a bivalent form. The monovalent form is based on Zaire ebolavirus, which is the cause of the current epidemic. The bivalent form is based on Sudan ebolavirus. Both forms will be tested in a nonrandomized trial with 60 adult volunteers (Park, 2014). The trial will evaluate the safety, side effects, and immunogenicity of the vaccines (Kanapathipillai et al., 2014). The phase 1 clinical trial consisted of 20 healthy adults, with 10 each being injected intramuscularly at one of two dosage rates. All 20 volunteers developed Ebola antibodies within 4 weeks of injection. Volunteers that received the higher dose developed larger amounts of Ebola antibodies. There were no side effects, except for a short duration fever in only 2 of the

Get Access